Drugs like Ozempic and Wegovy could raise the risk of a rare form of vision loss, but we are still trying to unpick why ...

It wasn’t until the 1930s, when scientists first demonstrated that rats that ate drastically less tended to live longer, that ...

For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION).

Semaglutide use in patients with type 2 diabetes moderately increases the risk of nonarteritic anterior ischemic optic neuropathy.

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.

Patients using popular weight loss medications, such as Ozempic and Wegovy, are being urged to undergo eye examinations due ...

Opens in a new tab or window Semaglutide was tied to a small risk of nonarteritic anterior ischemic optic neuropathy (NAION) in adults with type 2 diabetes. The risk was more modest than ...

Researchers found that among semaglutide users, the incidence rate of nonarteritic anterior ischemic optic neuropathy was 14.5 per 100,000 person-years. HealthDay News — For individuals with ...

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and ...

Increase in NAION associated with semaglutide use among individuals with type 2 diabetes. (HealthDay News) — For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly ...

For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION), according to a study published ...